Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions worldwide. The company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and by patients at home under physician supervision. It manufactures products in 29 countries and sells them in approximately 100 countries. Business Segments and Products The company operates in two segments, BioScience and Medical Products. BioScience This segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. Additionally, the BioScience business is investing in new disease areas, including oncology, as well as emerging technology platforms, including gene therapy and biosimilars. The company’s BioSurgery consists of biological products and medical devices used in surgical procedures for hemostasis, tissue sealing, adhesion prevention, soft tissue repair, and microsurgery products. Medical Products This segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The company provides products and services related to pharmacy compounding, drug formulation and packaging technologies. The company also provides products and services to treat end-stage renal disease, or irreversible kidney failures, along with other renal therapies, which business was enhanced through the 2013 acquisition of Gambro AB (Gambro). The company offers a portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis, home hemodialysis, continuous renal replacement therapy and additional dialysis services. The company’s BioPharma Solutions principally include sales from the pharmaceutical partnering business. Sales and Distribution The company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. In the United States, third parties, such as Cardinal Health, Inc. warehouse and ship a significant portion of the company’s products through their distribution centers. These centers are generally stocked with adequate inventories to facilitate prompt customer service. Sales and distribution methods include frequent contact by sales and customer service representatives, automated communications through various electronic purchasing systems, circulation of catalogs and merchandising bulletins, direct-mail campaigns, trade publication presence and advertising. International sales are made and products are distributed on a direct basis or through independent distributors or sales agents in approximately 100 countries. International Operations The majority of the company’s revenues are generated outside of the United States and geographic expansion remains a core component of the company’s strategy. Baxter’s international presence includes operations in Europe (including Eastern and Central Europe), the Middle East, Africa, the Asia-Pacific, Latin America and Canada. Research and Development For the year ended December 31, 2014, the company’s research and development expenses were $1.4 billion. Government Regulation The Food and Drug Administration (FDA) in the United States, the European Medicines Agency in Europe, the State Food and Drug Administration in China, and other government agencies inside and outside of the United States, administer requirements covering the testing, safety, effectiveness, manufacturing, labeling, promotion and advertising, distribution and post-market surveillance of the company’s products. In the United States, the company is subject to the oversight of FDA, Office of the Inspector General within the Department of Health and Human Services (OIG), the Center for Medicare/Medicaid Services, the Department of Justice, Environmental Protection Agency, Department of Defense and Customs and Border Protection in addition to others. The company’s activities are subject to regulation by Center for Medicare/Medicaid Services and enforcement by OIG and the Department of Justice. In each jurisdiction outside the United States, the company’s activities are subject to regulation by government agencies including the European Medicines Agency in Europe, the China Food and Drug Administration in China and other agencies in other jurisdictions. History Baxter International Inc. was founded in 1931. The company was incorporated under Delaware law in 1931.
baxter international inc
(BAX:New York Consolidated)
One Baxter Parkway
Deerfield, IL 60015
|Danone SA||€59.20 EUR||+1.21|
|Fresenius SE & Co KGaA||€58.57 EUR||+0.73|
|Kimberly-Clark Corp||$107.85 USD||+1.88|
|Stryker Corp||$96.07 USD||+0.50|
|Takeda Pharmaceutical Co Ltd||¥5,966 JPY||+96.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.